US2003012769A1PendingUtilityA1

Non-primate lentiviral vectors and packaging systems

Priority: Sep 24, 1997Filed: Dec 21, 2001Published: Jan 16, 2003
Est. expirySep 24, 2017(expired)· nominal 20-yr term from priority
C12N 15/86C12N 2740/15043C12N 2840/20
50
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides non-primate lentiviral vectors, packaging cells and packaging plasmids based, for example, on feline and ungulate retroviruses. In particular, the packaging plasmids are designed for expression in human cells (which are also used as packaging cells). The vectors of the invention transduce human cells, including difficult to target non-dividing cells of the hematopoietic and nervous system, in vitro and in vivo. The vectors are suitable for general gene transfer to these cells and for gene therapy to treat conditions mediated by these non-dividing cells including cancer and HIV infection.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A lentivirus transfer vector comprising a 5′ LTR and a 3′ LTR, each of which contains a U3 region, wherein a part or all of a regulatory element of the U3 region of the 5′ LTR is replaced by another regulatory element, operable in a mammalian cell, which is not endogenous to said lentivirus.  
     
     
         2 . The transfer vector of  claim 1 , wherein one or more nucleotide bases of the U3 region of the 3′ LTR are deleted.  
     
     
         3 . The transfer vector of  claim 1 , wherein said regulatory element not endogenous to said lentivirus is a cytomegalovirus enhancer, promoter or enhancer/promoter.  
     
     
         4 . The transfer vector of  claim 1 , wherein said regulatory element not endogenous to said lentivirus is a Rous sarcoma virus enhancer, promoter or enhancer/promoter.  
     
     
         5 . The transfer vector of  claim 1 , wherein said transfer vector further comprises a heterologous gene.  
     
     
         6 . The vector of  claim 1 , wherein said lentivirus is human immunodeficiency virus (HIV).  
     
     
         7 . The transfer vector of  claim 2 , wherein said U 3  region deleted is all of said U3 region except for a 5′ terminal dinucleotide and an att sequence.  
     
     
         8 . The transfer vector of  claim 7 , wherein said U 3  region deleted includes a TATA box sequence.  
     
     
         9 . The transfer vector of  claim 6 , wherein said HIV is HIV-1.

Join the waitlist — get patent alerts

Track US2003012769A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.